Pharmacoeconomic advantages of using intrauterine levonorgestrel containing Mirena system in conjunction with the transdermal estrogen containing drugs for the treatment of menopausal syndrome and contraception during the menopausal transition

Abstract

The current article provides the pharmacoeconomical comparison of cost-effectiveness between combined preparations for treatment of climacteric syndrome and IUD Mirena combined with trans-dermal estrogen formulations.

Keywords

• intrauterine levonorgestrel-containing system mirena
• trans-dermal estrogens
• combined mht
• pharmacoeconimic cost-effectiveness
• contraception